Prepare for the 2024 Financial Year-End: Lessons from Shannon Csapilla

Connecticut, US, 3rd December 2024, ZEX PR WIRE, As the end of the 2024 financial year approaches, now is the perfect time to reflect, plan, and prepare for future financial success. Shannon Csapilla, a finance professional based in Stamford, Connecticut, shares practical insights to help individuals make confident decisions about their financial goals and personal growth.

With a degree in Economics from the University of Rhode Island and years of experience in financial services, Shannon has built a career centered on helping others navigate complex challenges and create sustainable habits for long-term success.

“Financial planning isn’t just about numbers,” Shannon explains. “It’s about understanding what matters most to you and creating a plan to support that vision. Small, consistent steps can make a big difference.”

End-of-Year Habits to Build for Financial Success

Shannon emphasizes that preparation for the financial year-end doesn’t have to be overwhelming. Her advice focuses on simple, effective strategies:

  • Review and Adjust Your Goals: The end of the year is an ideal time to evaluate progress and realign your financial goals. “Take a moment to ask yourself if your current plan matches your priorities,” Shannon advises.

  • Stay Organized: Whether it’s managing receipts for tax season or tracking expenses, having a clear system reduces stress. “Use tools like apps or spreadsheets to stay on top of deadlines and details,” Shannon suggests.

  • Invest in Yourself: Lifelong learning and personal growth are essential. “Even outside of finances, learning new skills or exploring new interests keeps you adaptable,” she adds.

Balancing Challenges and Successes

Shannon acknowledges that building financial habits—and habits in general—isn’t always easy.

“Sometimes, time management is a challenge,” Shannon admits. “Balancing multiple responsibilities can feel overwhelming, but prioritizing and setting boundaries has helped me find balance.”

Despite these challenges, Shannon finds joy in the impact she makes. “The best part of my work is seeing someone feel more confident and secure in their plans,” she shares.

As 2024 draws to a close, Shannon encourages everyone to focus on progress over perfection.

“Reflect on what you’ve accomplished and where you want to go,” she says. “Even small changes, like setting up automatic savings or simplifying your budget, can have a big impact.”

For more insights and practical advice, Shannon encourages others to reach out through professional networks or local financial workshops.

About Shannon Csapilla
Shannon Csapilla is a finance professional based in Stamford, Connecticut, with a Bachelor’s Degree in Economics from the University of Rhode Island. She is passionate about helping others achieve financial stability and growth while promoting lifelong learning and mentoring young professionals.

Media Contact

Shannon Csapilla

https://www.shannoncsapilla.com/

https://www.linkedin.com/in/shannoncsap

Larry Weltman Spotlighted in New Online Business Feature

Ontario, Canada, 3rd December 2024, ZEX PR WIRE, Larry Weltman, a seasoned expert in the commission advance sector, is the subject of a recent online interview.  With almost two decades of experience, Weltman shares insights into his innovative use of technology, client-focused approach, and the lessons that have guided his journey.

The feature delves into Weltman’s transition from South Africa to Canada, and how his accounting background prepared him to meet the unique challenges of his field. He discusses the critical role commission advances play in helping realtors manage cash flow during closing delays, noting that “providing tailored solutions has always been about simplifying agents’ lives so they can focus on their work.”

Weltman also emphasizes the importance of adapting to digital transformation, detailing how automated tools have streamlined commission advance services, enabling realtors across Canada to operate with greater efficiency and transparency. He reflects on the values that have shaped his career, such as teamwork, resilience, and relationship-building—qualities inspired by his love of soccer and his early professional experiences.

The interview highlights Weltman’s dedication to mentorship and his vision for the future of commission advances, including exploring AI and data-driven tools to better serve realtors. Readers can explore his perspectives on building client relationships, navigating market challenges, and embracing innovation by accessing the full interview here. This feature provides a compelling look at his impact on the commission advance industry and his unwavering support for real estate agents.

To read the full piece, visit the website here. 

SOFTECH TEXAS LLC Announces U.S.’s First NFC Chip Factory, Transforming the Future of Smart Technology

SOFTECH TEXAS LLC announces plans to build the first NFC chip manufacturing factory in the U.S., marking a major milestone for domestic smart technology production. This initiative aims to reduce reliance on international suppliers, boost innovation, and strengthen the U.S. tech manufacturing landscape.

Houston, TX, 3rd December 2024, ZEX PR WIRE, SOFTECH TEXAS LLC, a trailblazer in NFC, GPS, and AR technologies, announces its plan to establish the first-ever NFC chip manufacturing factory in the United States. This ambitious project marks a significant milestone in the domestic production of NFC technology, positioning SOFTECH TEXAS LLC as a leader in the tech industry while driving innovation and economic growth.

With its roots in creating cutting-edge NFC-enabled products, SOFTECH TEXAS LLC aims to expand its impact by entering the manufacturing sector, ensuring greater control over production, quality, and innovation. This move will support the company’s commitment to delivering world-class NFC products while contributing to the advancement of the U.S. tech manufacturing ecosystem.

Innovative Brands Leading the Way

SOFTECH TEXAS LLC is already revolutionizing industries with its portfolio of eight smart brands, each showcasing the versatility and potential of NFC, GPS, and AR technologies:

  1. QOIKY (Smart Business Cards)

  2. CONIAX (Smart Magnets, Photos, and Canvases)

  3. KORBLE (Smart Greeting Cards)

  4. BORBLE (AR Coloring Cards)

  5. TAPY CAR (Smart Auto Dealer Signs)

  6. TAPPAX (Smart Luggage Tags)

  7. PETIOX (Smart Pet Tags)

  8. RINGOWE (Smart Love Rings)

Driving Innovation with Industry Leaders

Behind this bold venture are SOFTECH TEXAS LLC’s visionary leaders:

  • Ozkan Oz, Founder and inventor of globally recognized products such as CONIAX and KORBLE.

  • Ferhat Simsek, Co-Founder and owner of Lone Star Marble, a leader in the marble and pool industries.

  • Servet Ciltas, Co-Founder and owner of Corumar Marble, renowned for his extensive success in the U.S. market.

  • Selcuk Kaya, Strategic Partner for Softech Texas, will be Co-founder of the First NFC Factory and owner of KAYALAR MOTORS.

Together, they bring a unique blend of entrepreneurial vision, technological expertise, and business acumen to drive the company forward.

The Future of NFC Manufacturing in the U.S.

With the establishment of its NFC manufacturing facility, SOFTECH TEXAS LLC aims to:

  • Reduce reliance on international NFC chip suppliers.

  • Enhance product customization and innovation.

  • Create jobs and contribute to the U.S. economy.

About SOFTECH TEXAS LLC

SOFTECH TEXAS LLC is a pioneering technology company specializing in NFC, GPS, and AR applications. With plans to open the first NFC chip manufacturing factory in the United States, the company is poised to lead the future of smart technology. From groundbreaking products to cutting-edge manufacturing, SOFTECH TEXAS LLC is setting a new standard in innovation.

For more information, visit softechtexas.com.

Prop Firms vs. FX Brokers: Which Is Your Best Choice?

IMG_256

In the financial markets, traders typically choose between FX brokers and prop firms, the two most popular trading platforms. Understanding their differences is essential for selecting the one that aligns with your trading goals.

Prop Firms vs. FX Brokers

1. Capital Support and Risk Control

On FX broker platforms like XM, Exness, and IG, traders must use their own funds. All trading risks are borne by the individual, meaning that traders with limited capital may face substantial risks.

In contrast, Prop Firms like Funding Pips, FTMO, and Funded Knight offer traders access to significant capital, allowing them to trade without risking their own money. For example, with Funded Knight, traders only need to pay around $1,000 for an evaluation and can trade with up to $250,000 in real trading capital (the evaluation fee is refundable). With such large capital backing, traders have the flexibility to implement more complex strategies, allowing them to fully unleash their trading potential. They can also set proper stop-loss and take-profit levels according to the size of the account, reducing the risk of premature exits caused by limited funds.

2. Trading Costs and Profit Sharing

Traditional FX brokers generate revenue through spreads, commissions, and fees without offering profit-sharing. This model leaves traders solely responsible for their success or failure, with high trading costs often reducing profitability.

On the other hand, Prop Firms often offer higher profit-sharing rates. For example, after passing the evaluation challenge with Funded Knight, traders can earn up to 95% of the profit, which is the highest percentage among Prop Firms. With the mission “Your success is our success,” Prop Firms share a mutual interest with traders, offering free, high-quality educational resources, training courses, and professional consulting to help traders succeed.

3. Entry Barriers to Trading

Traditional FX brokers focus on platform conditions and market access. Traders can start trading immediately by depositing funds, without the need to pass any evaluation. However, this model often leads to higher risk for traders, especially when capital is insufficient, making it difficult to weather market volatility.

Since Prop Firms fully bear the risk of any loss traders might incur, they usually set up evaluation stages and trading rules to assess traders’ skills and risk management abilities. While this may result in higher entry barriers compared to FX brokers, it is not difficult for traders to meet these requirements. For example, Funded Knight sets relatively low evaluation standards and offers a quicker, simpler “1-step challenge” that allows traders to access real trading faster than the typical two-phase evaluation process. The “1-step challenge” even has no time or minimum trading day limits, which encourages more potential traders to participate.

Additionally, Funded Knight has tailored its services to meet the needs of traders in Asia, particularly Southeast Asia. It provides multilingual support and integrates popular local payment gateways, ensuring a seamless trading experience for the region’s traders.

Summary

Returning to the original question: should individual traders choose Prop Firms or FX Brokers?

For traders with substantial capital and a preference for full control, traditional FX brokers may be suitable. However, if overcoming capital limitations and maximizing profitability are your priorities, prop firms like Funded Knight provide an ideal trading environment to achieve these goals.

Learn more: https://fundedknight.com

Company Name: FK FINTECH LIMITED

Contact Person: Funded Knight Support

Email: support@fundedknight.com

State: Hong Kong

Website: https://fundedknight.com

China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia

SHENZHEN, CHINA – China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 2 December 2024, the Group through a wholly-owned subsidiary of the Company entered into an Exclusive Commercialization Agreement (the “Agreement”) with Atom Therapeutics Co., Ltd (hereinafter referred to as “Atom Therapeutics”, formerly named as “Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.”) of class 1 innovative drug ABP-671 for the treatment of gout and hyperuricemia (the “Product”). In accordance with the Agreement, the Group is entitled to an exclusive commercialization right of the Product in Mainland China, Hong Kong Special Administrative Region and Macao Special Administrative Region. The term of cooperation commences on the effective date of the Agreement and extends for ten years from the date the Product is first approved for market launch in Mainland China (the “Authorization Term”). Upon the expiration of the Authorization Term, it may be automatically renewed for an additional ten years, subject to specific conditions stipulated in the Agreement.

 

ABP-671 is a class 1 innovative chemotherapeutic drug for the treatment of gout and hyperuricemia, currently in Phase 2b/3 clinical trials for gout in China and overseas. The Product reduces renal re-absorption of uric acid by inhibiting Urate Anion Transporter 1 (URAT1). The results of two completed phase 2 clinical trials demonstrated favorable efficacy and safety profiles across multiple dose groups (ranging from 1 mg to 12 mg) of ABP-671. The 2 mg once-daily dosage of the Product was proved to be as effective as, or even better than, benzbromarone or febuxostat (maximum dosage of 80mg). The reduction in uric acid levels was sustained throughout the 24-hour period, with no significant safety concerns identified. This product is anticipated to offer more effective and safer treatment alternatives for patients suffering from gout and hyperuricemia[1]. Multiple patents in regard to substance and use of the ABP-671 have been granted in China.

 

Hyperuricemia is defined as a fasting blood uric acid level exceeding 420μmol/L (7.0 mg/dL) in adults on a normal purine diet on two separate days. The deposition of urate crystals in hyperuricemia patient results in arthritis, medically termed gout. Hyperuricemia and gout can cause acute and chronic inflammatory injury in articular cartilage, bone, kidney and vascular wall, which can lead to multiple organ damage of the heart, brain and kidney, etc. The data presented in the White Paper on Hyperuric Acid and Gout Trends in China (2021) indicates that, the incidence rate of hyperuricemia is 13.3%, with approximately 177 million hyperuricemia patients and the incidence rate of gout is 1.1% in general, with about 14.66 million gout patients in China. Frost & Sullivan indicates that, the number of people with hyperuricemia and gout in China will continue to increase in the future, reaching 240 million and 52.2 million respectively by 2030. Currently, the commonly used uric acid-lowering drugs in clinical practice in China are those which inhibit uric acid synthesis or promote uric acid excretion. Due to certain limitations in the efficacy and safety of the marketed uric acid-lowering drugs, such as causing renal failure, sudden cardiac death or severe liver toxicity. There is still an urgent need for effective and safe uric acid-lowering drugs among gout and hyperuricemia patients in China.

 

ABP-671 is currently with the potential to be the promising and safe product for the treatment of gout and hyperuricemia. Through this collaboration, it fills the blank in the CMS’s product portfolio of the treatment of gout. Gout and hyperuricemia are both rheumatic diseases and chronic metabolic diseases, which are highly consistent with the Group’s strategic layout in the cardio-cerebrovascular/ gastroenterology business and the network resources of marketed products. If approved for marketing in the future, the Product will synergize with the Group’s marketed product Metoject (methotrexate injection) in rheumatology and with Elcitonin (elcatonin injection) in endocrinology and orthopedics, in terms of expert network and market resources. Based on the unmet clinical needs and the expected solid clinical data of the Product, the Group is looking forward to the smooth advancement of the clinical development of ABP-671, allowing patients with relevant indications to benefit from this innovative treatment sooner.

 

About ATOM THERAPEUTICS

Atom Therapeutics was founded in March 2012, focused on the research and development of innovative drugs with global commercial value and competitiveness in the metabolic and inflammatory area. Atom Therapeutics’s main core team members come from the United States, with extensive experience in the research and development of innovative drugs. Atom Therapeutics has achieved remarkable development in the past few years. Atom Therapeutics’s core product ABP-671 is under pivotal clinical stage for the treatment of chronic gout. Atom Therapeutics’s another small molecule innovative drug named as ABP-745, used for indications in the field of anti-inflammatory immune indications. The Phase 1 clinical of ABP-745 exhibited outstanding pharmacokinetics and safety. The clinical trial is on the verge of entering Phase 2. For more information about Atom Therapeutics and its pipeline, please visit https://www.atombp.com/.

 

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.

 

Reference:

  1. The results of Phase 2 clinical trials was published and can be found at: https://www.atombp.com/2023/03/01/atom-bioscience-announces-positive-results-of-phase-2a-china-clinical-trial-of-its-urat1-inhibitor-for-chronic-gout/

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.

CHN Energy discussed upcoming investment activities in Kazakhstan

Chairman of the Management Board of JSC “NC “KAZAKH INVEST” Yerzhan Yelekeyev met with the management of the Chinese company CHN Energy, during which the parties discussed implementing an investment project for the construction of a coal chemical plant in Kazakhstan.

Earlier this September, a technical delegation from CHN Energy arrived in Kazakhstan to explore cooperation opportunities. During the visit, the company’s delegation visited three coal fields to assess the potential of coal mining regions. Further, in November this year, on the sidelines of the Kazakhstan Round Table on Global Investments (KGIR-2024), the Ministry of Industry and Construction of the Republic of Kazakhstan, KAZAKH INVEST, and CHN Energy signed an agreement on the implementation of a project for the production of carbon chemical products worth $4 billion.

During the meeting, Chinese representatives shared the first results of joint work within the framework of the agreement reached. So, the company decided to open a representative office in Astana.

“Given the significant coal reserves in Kazakhstan and the gradual abandonment of coal-fired energy generation, the coal industry needs a new development strategy. Its key element will be the transition to carbon chemistry, which will open up new opportunities for industry growth and transformation. Currently, the share of products produced from coal in Kazakhstan is only 3%. However, preliminary calculations show that the untapped potential of the industry reaches $25 billion. This indicates significant opportunities for investment and cooperation. I hope that with our support, your company will be able to identify priorities for the effective implementation of the first coal chemistry project in Kazakhstan, which will contribute to the accelerated development of the industry and will allow the export of coal chemical products to China, Central Asia, and Europe,” said Y. Yelekeyev.

Representatives of CHN Energy also expressed their willingness to consider new areas for cooperation, including the construction of renewable energy stations and gas chemical complexes, as soon as the implementation of the coal chemical project reaches a more active phase. At the end of the meeting, the parties agreed to continue active work on the project’s implementation and further strengthen investment cooperation.

For reference:

The company is a pioneer leader in the development of the coal chemical industry in China and one of the largest companies in the world for the extraction and processing of coal, as well as the production of thermal and wind energy. CHN Energy’s overseas assets are in South Africa, Australia, Indonesia, Greece and Germany. The company operates 97 coal mines with an annual coal production capacity of 685 million tons. CHN Energy also has 28 coal liquefaction plants, processing raw materials into liquid fuels with a production volume of 5.26 million tons per year and into olefins with a production volume of 3.93 million tons yearly.

The Rise of AI Agents: $KOLZ Sells Out in Presales as Users Unlock 24/7 Access to Top Influencers

Barcelona, Spain — $KOLZ has cemented its place as a leader in the AI agent hype, selling out three presale rounds on Gempad in minutes (raising over $200k+) and closing an additional $188k+ on Poolz. With the $KOLZ Token Generation Event (TGE) slated for early December, the platform is set to redefine influencer engagement in Web3. 

“KOLZ is not just a platform, it’s the future of influencer engagement, combining cutting-edge AI with real-world utility,” said Rebecca Forsyth, CEO of KOLZ. KOLZ merges AI and blockchain technology to create lifelike digital replicas of top crypto influencers. These replicas provide users with 24/7 access to trading insights, strategies and interactive Q&A sessions. 

Early adopters are already interacting with replicas of names like Satoshi Club, Ansem and 1Minute, with full functionality launching through a subscription model post-TGE. To ensure transparency, KOLZ will burn any unsold tokens from public and private sales before TGE, reinforcing its commitment to a healthy token economy. 

This innovative approach taps into the growing trend of AI agents, which are transforming how users engage with digital personalities. Unlike traditional influencer platforms, KOLZ ensures interactions are scalable, accessible, and highly personalized, setting a new standard for user experiences in Web3.

Looking ahead, KOLZ plans to onboard more high-profile influencers, launch staking and rewards systems, and introduce NFT functionality in 2025. The platform aims to expand globally, integrating with DeFi protocols and launching premium features like gamified learning and live events.

About KOLZ

KOLZ is a cutting-edge Web3 platform that uses advanced AI technology to connect users with AI replicas of top crypto influencers. By delivering 24/7 access to personalized insights, strategies, and meaningful conversations, KOLZ empowers traders and fosters a vibrant community centered on shared knowledge and growth.

For more information, visit: https://linktr.ee/kolzchat

Contact:

Name: Rob Spitz

Position: Social Lead

Email: contact@kolz.chat

How Pse.USDT Supports Renewable Energy Certificates in Solar Markets

In the global transition towards clean energy, Renewable Energy Certificates (RECs) have emerged as a critical market tool and a key driver of renewable energy market growth. RECs not only certify the use of clean energy for businesses and individuals but also create additional revenue streams for green energy producers. However, the traditional REC trading model faces challenges due to complex processes and a lack of transparency. With the introduction of Pse.USDT, blockchain technology and the USDT stablecoin come together to provide an efficient, transparent solution for the creation, trading, and verification of RECs, significantly supporting the sustained growth of the solar market.

A renewable energy certificate is a digital certificate representing clean energy attributes. When a solar photovoltaic system generates a certain amount of electricity, it can produce a corresponding amount of RECs. Each certificate represents a specific volume of green energy production and can be traded separately from electricity. In the traditional model, REC trading often requires multiple intermediaries, making the process complex, time-consuming, and lacking transparency, which can raise concerns about the authenticity of certificates.

Pse.USDT injects new possibilities into the creation and management of RECs through blockchain technology. Each REC generated on the platform is assigned a unique identifier via blockchain, including details such as the certificate’s origin, generation time, and associated energy production data. This information is recorded on the blockchain, ensuring it is immutable and traceable. Both buyers and sellers can verify the authenticity and validity of certificates in real-time through the platform, greatly enhancing market confidence. Furthermore, Pse.USDT’s automated smart contract feature makes the REC trading process more convenient and efficient, minimizing human errors or delays.

Unlike traditional trading methods, Pse.USDT also introduces the USDT stablecoin as a medium of exchange, mitigating the risks associated with price fluctuations in the REC market. Pegged to the U.S. dollar, USDT provides a stable value reference for both trading parties. This stability not only reduces uncertainty in transactions but also attracts more investors and consumers to the REC market, making the flow of green energy in the solar market more active and stable.

In terms of application scenarios, Pse.USDT’s platform supports multiple aspects. For energy producers, RECs offer an additional revenue stream and increase the attractiveness of solar photovoltaic system investments, encouraging more companies and individuals to enter clean energy production. Through Pse.USDT, producers can easily sell RECs to companies seeking to meet sustainability goals or regulatory requirements, quickly converting certificates into value. For corporate buyers, RECs are not only essential tools for achieving environmental responsibility but also crucial for enhancing brand image and market competitiveness. By purchasing these certificates, companies can demonstrate their use of renewable energy, comply with regulatory requirements, and showcase their commitment to environmental initiatives.

Pse.USDT’s advantages are also evident in international and diversified trading support. As global demand for green energy grows, cross-border transactions are gradually becoming an essential trend in the REC market. However, different countries and regions often have varying rules regarding REC certification and trading, increasing the complexity of transactions. Pse.USDT leverages blockchain technology to enable seamless cross-border transactions, ensuring interoperability between markets while reducing transaction costs and time. This model opens up broader development opportunities for the solar market and provides a more efficient solution for the global proliferation of clean energy.

Looking ahead, Pse.USDT plans to further optimize its support for renewable energy certificates and expand its platform services. For instance, the platform will introduce artificial intelligence and data analytics to provide users with real-time market trends and price forecasts, helping them make more informed trading decisions. Additionally, the platform will strengthen cooperation with international energy agencies and regulatory bodies to promote REC standardization, creating a more stable and fair trading environment for the market.

Pse.USDT is not just a technology platform but a critical driving force in the global energy market transformation. By supporting the creation, management, and trading of RECs, Pse.USDT provides a more efficient and transparent solution for the flow of green energy in the solar market. Looking to the future, Pse.USDT will continue to lead technological innovation and model transformation in the solar market, creating more possibilities for the global adoption and application of clean energy. With the participation of more regions and industries, Pse.USDT is poised to become an essential cornerstone for global green energy development, contributing irreplaceable strength to achieving carbon neutrality.

With an expanding network of participating regions and industries, Pse.USDT is poised to become an indispensable cornerstone for global green energy development. The platform’s commitment to transparency, efficiency, and international cooperation positions it as a leading force in the journey toward a carbon-neutral future. As countries and corporations unite in their pursuit of sustainability and climate resilience, Pse.USDT will continue to provide the tools and infrastructure needed to meet ambitious carbon reduction targets. By empowering both producers and consumers to engage meaningfully in the green energy economy, Pse.USDT is making an irreplaceable contribution to building a cleaner, greener, and more sustainable world for generations to come.

Contact name: Saif

Company name: HRG

Website https: https://hrginvestment.com/

Country: UAE

Mitolyn Launches Revolutionary Dietary Supplement to Transform Energy, Metabolism, and Aging Solutions

USA – DEC 02, 2024 – Mitolyn, a leader in health innovation, announces the launch of its groundbreaking dietary supplement, powered by the cutting-edge “Purple Peel Exploit.” This revolutionary formula harnesses the antioxidant-rich purple peel of the Maqui Berry to address pressing health concerns, including low energy, weight gain, and the effects of aging, by enhancing mitochondrial function—the core of cellular energy production.

“Mitolyn is more than a supplement—it’s a catalyst for transformative change,” said Mr. Peter Newman, Co-Founder of Mitolyn. “By focusing on mitochondrial health, we empower people to unlock their body’s natural potential to boost energy, metabolism, and overall vitality.”

The Science Behind Mitolyn

At the heart of Mitolyn’s innovation is the “Purple Peel Exploit,” a breakthrough that highlights the Maqui Berry’s unparalleled antioxidant properties. This unique supplement combines six natural, plant-based ingredients that work synergistically to improve mitochondrial efficiency:

  • Maqui Berry: Known for its rich antioxidants that reduce oxidative stress and support cellular health.
  • Rhodiola Rosea: Enhances endurance, focus, and stress management.
  • Haematococcus: A natural source of astaxanthin, revered for its anti-aging and anti-inflammatory properties.
  • Amla (Indian Gooseberry): Boosts immunity and metabolic performance.
  • Theobroma Cacao: Improves mood, energy levels, and overall well-being.
  • Schisandra: Promotes mental clarity, reduces fatigue, and supports adrenal function.

By targeting mitochondrial health, Mitolyn addresses the root causes of metabolic slowdown, providing a natural, sustainable solution to modern health challenges.

Tackling Modern Health Challenges

For adults aged 18 and above, Mitolyn offers a safe and natural alternative to synthetic supplements. With its 100% plant-based, non-GMO formula, Mitolyn provides a science-backed approach to improving energy, promoting fat loss, and reducing the visible effects of aging. The product is manufactured in an FDA-registered, GMP-certified facility, ensuring the highest safety and quality standards.

Dr. Nakamura, a prominent research scientist in mitochondrial health, noted:

“The Purple Peel Exploit is a breakthrough in health science. Mitolyn’s ability to naturally enhance mitochondrial function is transforming how we approach aging, energy levels, and metabolic health.”

Comprehensive Customer Benefits

Mitolyn not only provides health solutions but also offers exceptional value through its flexible pricing and customer-centric guarantees. The product comes with a 90-day money-back guarantee, allowing customers to experience its benefits risk-free.

For customers choosing multi-bottle packages, Mitolyn provides exclusive bonuses such as:

  • 1-Day Detox Kickstart eBook: A guide to quick and effective detoxification.
  • Renew You eBook: A resource packed with tips to support mental and physical wellness.

These additional resources complement Mitolyn’s benefits, offering a holistic approach to health and vitality.

Transforming Lives, One Cell at a Time

Mitolyn is more than a product; it represents a movement toward holistic, sustainable health. By addressing the root causes of aging and metabolic inefficiencies, Mitolyn offers a path to improved energy, sharper focus, and renewed vitality.

“Mitolyn isn’t just about quick fixes; it’s about empowering people to take control of their health at its core,” added Mr. Newman.

Availability

Mitolyn is now available for purchase exclusively through the company’s official website: https://mitolyn.com/welcome/?affiliate=mitoz&tid=miPR4 .

About Mitolyn

Mitolyn was founded by a dedicated team of health professionals with a mission to address core health challenges using nature-based solutions backed by rigorous science. The company’s innovative approach prioritizes mitochondrial health, offering products that target the root causes of energy depletion, metabolic slowdown, and aging.

“Health begins at the cellular level, and mitochondria are the foundation,” said Mr. Newman. “With Mitolyn, we’re starting a health revolution that focuses on these essential powerhouses of the body.”

Looking ahead, Mitolyn plans to expand its product line to include supplements aimed at cognitive enhancement, stress reduction, and other critical aspects of wellness. The company is also committed to raising global awareness about the importance of mitochondrial health through educational campaigns and partnerships.

Breaking News: Intercove Achieves Milestone Growth Among Australian Traders

Press Release Thumbnail

Intercove.net, the leading trading platform for Australian investors, is proud to announce a significant milestone in its journey toward transforming the trading experience for clients across the nation. The platform has achieved record-breaking growth, with an unprecedented increase in active users and trading volume over the past quarter.

The surge in growth reflects the platform’s commitment to delivering cutting-edge solutions tailored to the unique needs of Australian traders. By providing seamless access to trading opportunities, user-friendly tools, and robust security measures, Intercove.net continues to solidify its reputation as a trusted and innovative partner for financial growth.

 

Meeting the Needs of Australian Traders

Intercove.net’s remarkable growth highlights the increasing demand for reliable trading platforms in Australia. As market dynamics evolve, the need for transparent, efficient, and accessible trading tools has never been more critical. Intercove.net’s platform has proven to be a game-changer, offering solutions that empower clients to navigate complex markets with confidence and precision.

 

“This milestone is a testament to our unwavering dedication to meeting the demands of our users. We have invested in understanding the needs of Australian traders and delivering tools that support their financial goals,” said the CEO of Intercove.net. “Our success is built on the trust and loyalty of our clients, and we remain committed to maintaining the highest standards in the industry.”

 

Innovative Tools Driving Success

The platform’s recent enhancements have been pivotal in achieving this growth. With intuitive trading tools, advanced analytics, and robust risk management features, Intercove.net has enabled users to make informed decisions and maximize their potential returns.

Additionally, Intercove.net’s emphasis on providing seamless access to global markets has resonated with Australian traders. The platform’s reliability, transparency, and commitment to innovation have positioned it as a preferred choice for traders seeking a competitive edge.

“Intercove.net stands out because of its focus on innovation and simplicity. We strive to remove barriers and ensure that all traders, whether experienced or just starting, have access to the resources they need to succeed,” added the CEO.

 

Client-Centric Approach

Intercove.net’s growth is not solely attributed to its technology; the platform’s client-centric philosophy has played a vital role. The company places a high priority on customer satisfaction, offering unparalleled support and resources to help clients navigate their trading journey.

 

Through tailored educational materials, dedicated customer service, and a commitment to transparency, Intercove.net has cultivated a loyal user base that trusts its platform to deliver consistent results.

 

A recent report on client feedback highlighted the platform’s ease of use and effectiveness in supporting traders at all levels. From beginners to seasoned professionals, users have praised Intercove.net for its reliability, efficiency, and dedication to client success.

 

A Landmark Moment for Intercove.net

The record growth achieved by Intercove.net is more than a business milestone; it is a reflection of the platform’s ability to adapt and thrive in an ever-changing financial landscape. By addressing the evolving needs of its users and investing in continuous improvement, Intercove.net is setting new benchmarks for excellence in trading platforms.

“This achievement is only the beginning,” the CEO stated. “We are focused on the future and are committed to driving innovation, fostering trust, and creating a trading environment that supports success for every client.”

 

With its recent growth milestone, Intercove.net invites Australian traders to join the thousands of satisfied users who have already discovered the platform’s potential. Whether you are looking to explore new markets, optimize your trading strategies, or achieve financial goals, Intercove.net offers the tools and support to make it happen.

 

About Intercove.net

Intercove.net is a premier trading platform designed to meet the needs of modern investors. Offering innovative tools, reliable performance, and a client-focused approach, Intercove.net empowers traders to achieve their financial goals in a secure and user-friendly environment.

 

Disclaimer: Trading involves significant risk, and past performance does not guarantee future results. This content is for informational purposes only and should not be considered financial advice. Always conduct your own research and consult with a licensed professional before making financial decisions.

Company Information

Organization:intercove

Contact Person Name:Kristofer lewis

Webiste:https://intercovebot.com

Email:kris@intercovebot.com